DelveInsight's latest report reveals a robust pipeline for androgenetic alopecia with 80+ companies developing 100+ therapeutic candidates across various clinical stages.

Virios Therapeutics and Wex Pharmaceuticals have merged in an all-stock transaction, creating Dogwood Therapeutics (NASDAQ: DWTX), focused on clinical development of Halneuron®, IMC-1, and IMC-2.

Alnylam Pharmaceuticals Inc discussed their Q3 2024 earnings, focusing on advancements in RNAi therapeutics delivery, the progress of ALN-HTT02 in Phase 1 studies, market dynamics in the polyneuropathy sector, payer discussions for AMVUTTRA, and SG&A spending for upcoming launches.

A Phase I trial of LYMPHIR with pembrolizumab demonstrates a 27% objective response rate in patients with recurrent solid tumors.

Syros Pharmaceuticals anticipates pivotal complete response (CR) data from the SELECT-MDS-1 trial of tamibarotene in higher-risk myelodysplastic syndrome (HR-MDS) by mid-November 2024.

The FDA has approved Danziten (nilotinib) for adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) and those resistant or intolerant to prior therapies.

The FDA has approved Danziten, a new formulation of nilotinib, for adults with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML).

Jazz Pharmaceuticals' Biologics License Application (BLA) for zanidatamab, a HER2-targeted bispecific antibody, has been accepted by the FDA with Priority Review for biliary tract cancer.

KalVista Pharmaceuticals has filed a New Drug Application with the FDA and a Marketing Authorization Application with the EMA for sebetralstat, an oral therapy for hereditary angioedema (HAE).

Acumen Pharmaceuticals is progressing its Phase 2 ALTITUDE-AD trial of sabirnetug, an immunotherapy for Alzheimer's, with enrollment expected to complete in H1 2025.

PMV Pharmaceuticals is advancing PC14586 (rezatapopt) in a Phase 2 monotherapy trial (PYNNACLE) for solid tumors with p53 Y220C mutations, with interim data expected by mid-2025.

Vertex Pharmaceuticals is under investigation for potential securities fraud following disappointing Phase 2b trial results for suzetrigine.

Acumen Pharmaceuticals is developing sabirnetug (ACU193), a monoclonal antibody targeting toxic amyloid-beta oligomers, a primary cause of Alzheimer's disease.

Scilex Pharmaceuticals secured FDA agreement on the NDA path for SP-103, a lidocaine topical system 5.4%, following a successful end-of-Phase II meeting.

Syros Pharmaceuticals remains on track to complete enrollment in the SELECT-MDS-1 trial by Q4 2023 and announce pivotal complete response data in Q3 2024.

The FDA has granted approval to Revuforj (axatilimab) for the treatment of adult and pediatric patients 12 years and older with relapsed or refractory chronic graft-versus-host disease (cGVHD) after failure of one or two prior lines of systemic therapy.

PMV Pharmaceuticals reported a net loss of $69.0 million for 2023, an improvement from the previous year, with increased R&D investments focused on advancing rezatapopt.

The FDA has approved JOURNAVX™ (suzetrigine) as a first-in-class, non-opioid treatment for moderate-to-severe acute pain in adults.

Shuttle Pharmaceuticals has priced a $4.5 million public offering to fund clinical trials.

Citius Pharmaceuticals (Citius Pharma) achieved FDA approval for LYMPHIR for relapsed or refractory cutaneous T-cell lymphoma (CTCL).